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Abstract
Cellular prion protein (PrP
c) is a physiological constituent of eukaryotic cells. The cellular pathways underlying prions spread
from the sites of prions infection/peripheral replication to the central nervous system are still not elucidated. Membrane-
derived microvesicles (MVs) are submicron (0.1–1 mm) particles, that are released by cells during plasma membrane
shedding processes. They are usually liberated from different cell types, mainly upon activation as well as apoptosis, in this
case, one of their hallmarks is the exposure of phosphatidylserine in the outer leaflet of the membrane. MVs are also
characterized by the presence of adhesion molecules, MHC I molecules, as well as of membrane antigens typical of their cell
of origin. Evidence exists that MVs shedding provide vehicles to transfer molecules among cells, and that MVs are important
modulators of cell-to-cell communication. In this study we therefore analyzed the potential role of membrane-derived MVs
in the mechanism(s) of PrP
C diffusion and prion infectivity transmission. We first identified PrP
C in association with the lipid
raft components Fyn, flotillin-2, GM1 and GM3 in MVs from plasma of healthy human donors. Similar findings were found in
MVs from cell culture supernatants of murine neuronal cells. Furthermore we demonstrated that PrP
Sc is released from
infected murine neuronal cells in association with plasma membrane-derived MVs and that PrP
Sc-bearing MVs are infectious
both in vitro and in vivo. The data suggest that MVs may contribute both to the intercellular mechanism(s) of PrP
C diffusion
and signaling as well as to the process of prion spread and neuroinvasion.
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Introduction
Prion diseases are a complex group of fatal neurodegenerative
disorders that affect humans and a wide variety of animals and are
characterized by strong neuronal cell loss, spongiform vacuolation
and astrocytic proliferation [1]. According to the ‘‘protein-only’’
hypothesis PrP
Sc, the misfolded form of normal ,0cellular prion
protein (PrP
C), is the infectious agent that may convert PrP
C to
PrP
Sc in a self-propagating reaction [2]. Prions accumulate not
only in the central and peripheral nervous system but also in
extracerebral compartments, such as secondary lymphoid organs
and muscles. However, the only organ system in which severe
histopathological damage can be demonstrated as a consequence
of infection with prions is the nervous system. Prion diseases are
typically initiated by infection of peripheral sites, as in the case of
bovine spongiform encephalopathy (BSE), variant Creutzfeldt–
Jakob disease (vCJD), Kuru, and most cases of iatrogenic
Creutzfeldt–Jakob disease (iCJD). The mechanisms by which
prions spread from the site of peripheral exposure, such as the
gastrointestinal tract, to the lymphoreticular system where a first
replication phase occurs and subsequently to and within the
central nervous system are still not completely elucidated [3,4,5].
Although different cell types of the immune system, such as B
lymphocytes [6,7,8] follicular dendritic cells [9,10,11], macro-
phages [12,13] and dendritic cells [14,15,16,17], and the
peripheral nervous system [18,19,20] have been recognized as
key players in the process of prion neuroinvasion, relatively little
information is available about the mechanism(s) underlying
intercellular prion transfer.
Microvesicles (MVs) are submicron (0.1–1 mm) [21,22], mem-
brane-bounded vesicles which are released both from the cell
surface of normal healthy or damaged cells. Shedding of
membrane-derived MVs is a physiological phenomenon that
usually accompanies cell activation and growth. MVs are
characterized by the presence of adhesion molecules, MHC I
molecules, as well as of membrane antigens typical of their cell of
origin [21–23]. They are normal constituents of blood (5–50 mg/
ml), and are secreted by leukocytes, endothelium, platelets and
erythrocytes. The number of MV circulating in peripheral blood
increases during cell injury, apoptosis, inflammation, thrombosis
and platelet activation [23].
Although the molecular basis of protein sorting during MVs
formation is not fully understood, they result from an exocytotic
budding process involving lipids and proteins metabolism. The
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membrane surface, leading to the formation of MVs and their
release in the extracellular environment. Some evidence shows
that MVs components mainly arise from lipid rafts, which
therefore might be involved in setting up sorting platforms to
concentrate specific proteins within MVs, which could be destined
to extracellular secretion [24].
The functional role of MVs is still largely unknown, however
recent evidence suggests that MVs are important modulators of cell-
to-cell communication and play an important pleiotropic role in
many biological processes. Indeed, MVs may possibly act as
paracrine vectors of transcellular exchange of messages between
circulating and endothelial cells [24], participate in a variety of
intracellular adhesion processes, and induce cellular response(s) [23].
Exosomes, which measure about 50–90 nm in diameter, are
membrane vesicles released into the extracellular environment upon
exocytic fusion of multivesicular endosome with the cell surface.
They have a particular composition [26] reflecting their origin in
endosomes as intraluminal vesicles. It is assumed that exosomes are
non-plasma-membrane-derived vesicles. Moreover, exosomes may
‘‘hijack’’ infectious particles such as the immuno deficiency virus
(HIV) from the cytoplasm of the releasing cells [27,28] and possibly
even whole intact organelles such as the mitochondria [29].
The release of PrP
C and infectious PrP
Sc by prion infected
epithelial, neuroglial and neuronal cells in association with
exosomes has recently been highlighted [30–32], suggesting that
PrP
Sc-bearing exosomes may provide a mechanism for intercel-
lular transmission of infectious prions in addition to cell–cell
contact. It has furthermore been shown that endogenous PrP
C is
associated with exosomes released by blood platelets [33], and a
number of studies have demonstrated that prions are present in
blood and blood components, buffy coats, plasma, and platelets in
animal models [34,35]. It has also been demonstrated that blood
as well as plasma of animals experimentally infected with TSEs
can efficiently transmit prion infection by transfusion [35–37]. Of
concern, is the finding that vCJD is most probably efficiently
transmitted between human patients by blood transfusion [38–40].
This infection process, in the absence of sensitive vCJD blood tests
for screening of blood components donations, could lead to a
horizontal spread of vCJD within the human population.
The aims of this study were to evaluate the potential role of plasma
membrane-derived MVs in the mechanism(s) of PrP
C diffusion and
prion infectivity transmission invitro and invivo and to characterize the
interactions of PrP
C with lipid raft components in MVs. Here, we
demonstrate that PrP
Cis associated with MVs from plasma of human
healthy donors and with MVs shed by murine neuronal cells. We
further show that in MVs PrP
C associates with lipid raft components
such as Fyn, flotillin-2, GM1 and GM3. Furthermore, we
demonstrate for the first time that mouse neuronal Neuro-2a cells,
endogenously expressing murine PrP, release PrP
C and PrP
Sc in
association with plasma membrane-derived MVs when infected with
a mouse-adapted scrapie strain. Moreover, we show that PrP
Sc-
bearing MVs can transmit prion infectivity both in vitro and in vivo,
indicating that MVs contribute both to the intercellular mechanism(s)
of PrP
C diffusion and to the process of infectious prions intercellular
trafficking. We therefore postulate that MVs may act as carriers of
prion infectivity during prion neuroinvasion and may also contribute
to blood transfusion-mediated transmission of prion diseases.
Materials and Methods
Cell lines
Murine Neuro-2a cells (American Type Culture Collection
ATCC CCL 131) were maintained in DMEM (Sigma, Germany)
supplemented with 10% heat-inactivated fetal calf serum (FCS)
(Invitrogen, Germany), 4 mM L-Glutamin (Sigma, Germany) and
antibiotics (200 U/ml penicillin and 0.2 mg/ml streptomycin
(Sigma, Germany) at 37uC in a humidified 5% CO2 atmosphere.
Murine Neuro-2a PK1 cells and Rocky Mountain Laboratory
strain (RML)-infected Neuro-2a PK1 cells [41] were maintained in
Opti-MEM (Invitrogen, Germany) supplemented with 10% (FCS),
4 mM L-Glutamin and antibiotics (200 U/ml penicillin and
0.2 mg/ml streptomycin). The cell lines were maintained at
37uC in a humidified 5% CO2 atmosphere.
Antibodies
Monoclonal anti-PrP antibody 6H4 (Prionics Switzerland).
Anti-mouse immunoglobulin-colloidal gold (Biocell, UK). Mono-
clonal anti-PrP antibody SAF 32 (SPI Bio, Italy). Polyclonal anti-
PrP antibody C-20, polyclonal anti-PrP PE-conjugated antibody
(C-20 PE), polyclonal anti-Fyn antibody FYN3, polyclonal anti-
Flotillin-2 antibody, polyclonal anti-Tsg101 (M-19) were pur-
chased from Santa Cruz Biotechnology, (Santa Cruz, CA, USA).
Monoclonal anti-GM2 and anti-GM3 [42] were purchased from
Seikagaku (Corp. Chuo-ku,Tokyo, Japan). PE-conjugated anti-
mouse IgG, HRP-conjugated cholera toxin, B subunit (HRP-
CTxB), HRP-conjugated anti-mouse IgG (anti-mouse IgG-HRP),
HRP anti-mouse IgM (anti-mouse IgM-HRP), HRP-conjugated
anti-rabbit IgG (anti-rabbit IgG-HRP), HRP anti-goat IgG (anti-
goat IgG-HRP), IgG from goat serum with irrelevant specificity
(IgG irrelevant), monoclonal anti-GAP 43 antibody, were
purchased from Sigma Chem. Co. (St Louis, MO, USA). B-PE-
conjugated IgG from goat serum with irrelevant specificity (goat
IgG B-PE irrelevant) was purchased from ICN Biomedicals
(Milano, Italy). Monoclonal anti-Alix IgG1 3A9 was purchased
from Cell Signaling (USA) Anti-lyso-bis-phosphatidic acid (LBPA)
MoAbs were kindly provided by Dr Jean Gruenberg. PE-
conjugated anti-human MHC-I was purchased from eBioscience
(San Diego, CA, USA).
Preparation of platelet-free plasma samples for MVs
analysis
For platelet-free plasma preparation, 5 ml blood samples were
drawn by venipuncture into 0.129 M trisodium citrate. MVs were
separated from whole blood within 1 h by two sequential
centrifugations: 15 min at 1500 g, followed by a 1 min decanta-
tion at 13000 g to remove all the residual platelets or cell
fragments of similar size [43].
Fifty ml of platelet-free plasma were labeled with 2 mg anti-PrP
(C-20 PE), at +4uC. The fluorescence intensity was analyzed with a
IL Coulter cytometer (Coulter Electronics, Hialeah, FL) and
compared with a sample of platelet-free plasma, labeled with goat
IgG B-PE irrelevant. The size distribution of MVs was 0.1 to
1 mm; MVs were gated on the basis of forward angle light scatter
and 90u light scatter parameters, using polystirene latex beads
(Sigma, St Louis, MO, USA) 0.8 mm as standard. To distinguish
eventual residual platelets in our sample, we compared the MVs
preparation with a platelet-enriched plasma, stained by anti-CD41
MoAb (data not show).
Separately, in parallel experiments MVs, collected by centrifu-
gation at 200006g, were resuspended in 50 ml of sample buffer
and analyzed by Western Blot [44], using the anti-PrP 6H4, and
then anti-mouse IgG-HRP, anti-Fyn (FYN3) and then anti-rabbit
IgG-HRP, or anti-flotillin-2 and then anti-goat IgG-HRP.
Immunoreactivity was assessed by chemiluminescence reaction
using the ECL Western blocking detection system (Amersham
Biosciences). As a control, cells were separated from human
peripheral blood (PB) by centrifugation and resuspended in cold
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NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.5% SDS].
Lysates were pelleted at 200006g for 10 min at 4uC and
supernatants were transferred to a clean microfuge tube. Protein
concentration for cell lysates and MVs was determined by
Bradford assay as recommended by the manufacturer’s guidelines
(Roth, Germany).
Isolation of MVs from cell culture supernatants
Neuro-2a or Neuro-2a PK1 cells (2–4610
7 cells) were cultured
for 2–3 days prior to MVs isolation by sequential centrifugation
protocol [45,46]. Cellular debris was removed by two consecutive
centrifugation steps at 45006g for 5 min at RT. Supernatants
were centrifuged at 200006g for 1 h at 4uC. MVs were pooled,
washed in either PBS or Opti-MEM (Invitrogen), repelleted and
then either resuspended in Opti-MEM for in vitro or in PBS
(Invitrogen, Germany) for in vivo infection experiments or lysed
[20 mM Tris-HCl (pH 7.5), 1 mM EDTA, 100 mM NaCl, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.5% SDS] for
immunoblot analyses.
Immunoelectron microscopy
Neuro-2a PK1 cells were incubated with the anti-PrP 6H4
antibody for 1 h at 4uC. Cells were washed in PBS and then were
fixed with 1% paraformaldehyde for 1 h at 4uC, washed and
labeled with anti-mouse immunoglobulin-colloidal gold for 3 h at
4uC. Cells were post-fixed first in 2.5% glutaraldeyde for 45 min at
RT and then in osmium tetroxide 1% in Veronal acetate buffer,
pH 7.4, for 2 h at 4uC, stained with uranyl acetate (5 mg/ml),
dehydrated in acetone and embedded in Epon 812. Samples were
examined under an electron microscope (Zeiss, Germany).
Western blot analysis
Eighty micrograms of total protein of each cell lysate and 20 mg
of each MVs were electrophoresed through a 12% SDS
polyacrylamide gel. When proteinase K digestion was performed
prior to immunoblot analysis, 250 mg of cell lysates and 20 mgo f
MVs preparations were digested for 1 h at 37uC (0.1 mg or 0.3 mg
or 1 mg PK (Roche Diagnostics NL, Germany) per 20 mg total
protein). Proteinase K digestion was stopped with 1 mM
phenylmethylsulphonyl fluoride (PMSF, Sigma, Germany). Pro-
teins were transferred to PVDF membranes (Immobilon-P;
Millipore, USA) by semidry blotting. Membranes were blocked
at RT for 1 h with Tris-buffered saline/0.05% Tween 20 (TBST)/
5% nonfat dry milk, incubated with the appropriate primary
antibody diluted in Tris-buffered saline/0.05% Tween 20
(TBST)/1% nonfat dry milk (for PrP, anti-PrP SAF-32 or anti-
PrP 6H4; anti-GAP-43; anti-flotillin-2; anti-Fyn FYN3;, anti-Alix
3A9; anti-Tsg101 (M-19), overnight at 4uC. After washing with
TBST, membranes were incubated for 1 h at room temperature to
horseradish peroxidase-conjugated secondary antibody diluted in
the same buffer as above. Bands were visualized by enhanced
chemiluminescence (Amersham Pharmacia, Germany).
Immunoprecipitation experiments
Briefly, blood plasma-derived and Neuro-2a cells-derived MVs
were lysed in lysis buffer (20 mM HEPES, pH 7.2, 1% Nonidet P-
40, 10% glycerol, 50 mM NaF, including protease inhibitors).
After preclearing, the supernatant was immunoprecipitated with
anti-PrP polyclonal antibody C-20 plus protein A-acrylic beads.
The immunoprecipitates were split into two aliquots.
The first one was subjected to ganglioside extraction according
to the method of Svennerholm and Fredman [47]. The eluted
glycosphingolipids were dried and separated by high-performance-
thin-layer-chromatography (HPTLC) aluminium-backed silica gel
60 (20620) plates (Merck, Darmstadt, Germany). Chromatogra-
phy was performed in chloroform:methanol:0.25% aqueous KCl
(5:4:1) (v:v:v). Plates were immunostained for 1 h at room
temperature with HRP-CTxB, or, alternatively, with anti-GM2
IgM or anti-GM3 IgM and then with anti-mouse IgM-HRP.
Immunoreactivity was assessed by chemiluminescence reaction
using the ECL Western blocking detection system (Amersham,
Buckinghamshire, UK). Alternatively, the immunoprecipitates
were subjet to Western Blot analysis by anti-Fyn FYN3 and then
with anti-rabbit IgG-HRP.
The immunoprecipitates were checked by Western blot, using
the anti-PrP monoclonal 6H4 antibody.
In vitro infectivity assay
Noninfected Neuro-2a PK1 cells were seeded in six-well plates
24 hrs prior to infection. MVs were isolated both from uninfected
(MVs
Noninf) and RML-infected (MVs
Inf) Neuro-2a PK1 cells as
previously described and resuspended in Opti-MEM. MVs were
incubated for 48 hrs with noninfected Neuro-2a PK1 cells. RML
and mock brain homogenates (1% w/v homogenates) were
included as positive and negative controls, respectively. Prion
infection was assayed by the presence of PrP
Sc by cell blot assay.
Cell blot assay
Cells were cultured on glass coverslips (Roth, Germany) until
confluence, washed with CMF-PBS, and placed cell side down on
lysis buffer I [50 mM Tris-Cl, pH 8.0; 150 mM NaCl; 0.5% sodium
deoxycholate; 0.5% Triton X-100]-soaked nitrocellulose mem-
branes (Hybond-C-Extra, Amersham, Germany) that were previ-
ously laid on a lysis buffer-soaked filter paper. Membranes were then
processed as described [41]. Briefly, membranes were dried at RT,
coverslips were carefully removed and then the membranes were
incubated in a Proteinase K solution [5 mg/ml PK in lysis buffer] for
90 minat37uC.AftertwicewashindH20,PKdigestionwasstopped
by incubating the membranes in 2 mM PMSF for 10 min at RT.
Membranes werethan treated with 3 M guanidinium thiocyanate in
10 mM Tris-Cl (pH 8.0) for 10 min. After extensive washing in
dH20, membranes were processed for PrP
C/PrP
Sc detection by the
use of the anti-PrP 6H4 as described above.
In vivo infectivity bioassay
MVs were isolated both from uninfected and RML-infected
Neuro-2a PK1 cells, as previously described, and resuspended in
PBS, 0.2 ml. Uninfected and infected Neuro-2a PK1 cells were
collected and resuspended in 1 ml PBS. MVs and cells were
subjected to five consecutive cycles of freeze and thawing. Protein
concentration for cell lysates and MVs was determined by
Bradford assay, as recommended by the manufacturer’s guide-
lines. Samples were then adjusted to 10 mg total protein per 30 ml
with PBS/5%BSA. Different dilutions of mouse brain homogenate
infected with the Rocky Mountain Laboratory (RML) scrapie
strain (passage 5.0, 1610
8 LD50/ml 10% brain homogenate) [48]
in PBS/5% BSA were used as positive controls, whereas mock
infected brain homogenate was included as negative control.
Thirty microliters for each sample were administered intracere-
brally to groups of four tga20 mice [49]. Disease in animals was
diagnosed when at least three of the following symptoms were
observed: foot clasping of hindlegs when mice were lifted by the tail,
plastic tail; decreased motor activity; mincing gait, disorientation;
mild hind leg paresis, ataxia; kyphosis. Incubation time to terminal
scrapie sickness was determined and infectivity titers were calculated
by using the relationship y=11.4520.088 x,w h e r ey is logLD50/ml
Shedding of PrP
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used to calculate infectivity titres. The presence of a protease-
resistantisoformofPrP (PrP
Sc)intheinfectedbrainswas investigated
on proteinase K-treated (20 mg/ml; 30 min; 37uC) homogenates by
Western blot analysis, as described above.
Results
Presence and association of PrP
C and lipid raft
components in human plasma-derived microvesicles
MVs are normal constituents of blood plasma and are secreted
by leukocytes, erythrocytes, platelets and endothelium [50]. To
investigate the presence of PrP
C in cell membrane-derived MVs
from plasma obtained from healthy human peripheral blood
donors, MVs were isolated by sequential centrifugations from
platelet-free plasma preparations. Presence of PrP
C in the blood
plasma-derived MVs was first detected by immunoblot analysis by
the use of the monoclonal anti-PrP 6H4 antibody; PrP
C was
recognized such as shown in Figure 1A. As shown in Figure 1B,
PrP
C expression in MVs was confirmed by flow cytometry:
staining with the anti-PrP polyclonal antibody C-20 PE revealed a
specific PrP
C reactivity. These findings indicate the presence of
PrP
C on MVs isolated from human plasma. In order to check the
purity of MVs under the chosen test condition, two control
stainings were performed: (i) anti-LBPA, which is an endosome-
specific marker [51], thus representing an useful tool to identify
exosomes, but not MVs; (ii) anti-MHC I as a positive control for
MVs. As expected, MVs were virtually negative for anti-LBPA
staining, demonstrating the absence of exosomes in our prepara-
tion. However, a specific anti-MHC I staining was detected,
confirming both the isolation of MVs and the purity of the MV
preparation (Fig. 1).
Having previously demonstrated that PrP
C is strongly associated
with gangliosides GM1 and GM3 within lipid rafts on the surface
of lymphocytic cells [52,53], we investigated the presence of GM1
and GM3 in MVs from plasma of human healthy donors. Acidic
glycosphingolipids extracted from MVs were immunostained by
anti-GM3 antibody (MoAb GMR6) [42] or by HRP-CtxB, which
stains GM1 [54]. As shown in Figure 2, the presence of GM3
(Fig. 2A) and GM1 (Fig. 2B) in isolated MVs was clearly detected.
Since p59Fyn kinase as well as flotillin-2 have also been indicated
as raft components, which may be associated with PrP
C
[53,55,56,57], we then analyzed the presence of both proteins in
blood plasma-derived MVs. Western blot analyses showed a
59 kDa band specifically recognized by the anti-Fyn antibody
(Fig. 2C) and a 42 kDa band specifically recognized by the anti-
flotillin-2 antibody (Fig. 2D). The purity and enrichment of MVs
was shown by electron microscopy (Fig. 2E).
Direct interaction of PrP
C with gangliosides as well as with
p59Fyn kinase in plasma-derived MVs was assayed by coimmu-
noprecipitation followed either by TLC immunostaining for the
detection of gangliosides or conventional immunoblotting for
p59Fyn kinase detection. As shown in Figure 3, PrP
C associates in
MVs with the gangliosides GM3 (Fig. 3A) and GM1 (Fig. 3B) and
with the tyrosine kinase Fyn (Fig. 3C). These findings suggest that
raft components, strictly associated with PrP
C on the cell plasma
membrane, such as gangliosides, p59Fyn and flotillin-2, are
recruited during membrane blebbing which leads to MVs
formation.
Neuronal cells release membrane-derived MVs bearing
PrP
C and raft components
In order to determine whether neuronal cells can also release
plasma membrane-derived MVs and to investigate whether these
MVs also contain PrP
C associated with lipid rafts components, we
isolated MVs from cell culture supernatants of a murine neuronal
cell line (Neuro-2a) and from its subclonal line (Neuro-2a PK1)
[41]. The isolation of MVs from cell culture supernatants was
based on a sequential centrifugation steps protocol in which
increasing centrifugal forces were used. Plasma membrane-derived
MVs were collected at 200006g, a centrifugal force not sufficient
to enrich for exosomes. The presence of PrP
C was shown in MVs
released both by Neuro-2a (Fig. 4A) and Neuro-2a PK1 cells.
Electron microscopy analyses demonstrated the presence of
vesicles, often aggregated, with a size (from 100 nm to 1 mm)
compatible with MVs similarly purified from other cells (Fig. 4B)
[23]. In particular, immunogold labeling of Neuro-2a PK1 cells
revealed that PrP
C is unevenly distributed on the membrane of
MVs (Fig. 4B).
To exclude the presence of contaminating exosomes within the
MVs-enriched fraction, the levels of Tsg101 and Alix, both
cytoplasmic proteins previously identified as specific markers for
exosomes [46,58], were assessed by immunoblot analysis (Fig. S1).
The signals obtained in the MVs-enriched fraction were lower
than those observed in the exosome-enriched fraction.
Since we have shown that blood plasma-derived MVs contain
lipid raft components, such as Flotillin-2, gangliosides and, most
importantly, PrP
C, we analyzed the presence of these components
in MVs released by Neuro-2a cells by Thin Layer Chromatog-
raphy (TLC) immunostaining and immunoblot analyses (Fig. 5).
Since the main ganglioside constituent of Neuro-2a was GM2
[59], acidic glycosphingolipids extracted from MVs were immu-
nostained with a highly specific anti-GM2 antibody. As shown in
Figure 5A, the presence of GM2 in isolated MVs was detected. In
addition, neuronal cells-derived MVs also contained Flotillin-2
and the axonal membrane protein GAP-43, a neuronal protein
that binds to rafts via its acylated N-terminal.
Since gangliosides have been shown to be components of the
signaling complex within lipid rafts [60], we investigated the
association of PrP
c with ganglioside GM2 in MVs from Neuro-2a.
MVs were isolated by sequential centrifugations as above and
PrP
C was immunoprecipitated with the anti-PrP polyclonal
antibody C-20. Acidic glycosphingolipids extracted from the PrP
C
immunoprecipitates were analyzed by Thin Layer Chromatogra-
phy (TLC) immunostaining, using the anti-GM2 MoAb. The
results indicated that PrP
C associates with GM2 (Fig. 5B) within
MVs rafts. The immunoprecipitate was revealed as PrP
C,a s
detected by Western blot, using the anti-PrP monoclonal 6H4
antibody. In control samples the immunoprecipitation using IgG
with irrelevant specificity, under the same condition, did not result
in detectable levels of gangliosides.
These findings clearly indicate that neuronal cells actively
release membrane-derived MVs in addition to exosomes [61]. The
secreted MVs contain lipid raft components, suggesting that also in
the CNS MVs-based intercellular transmission of molecular
information could occur.
MVs secreted by neuronal cells harbour both PrP
Sc and
prion infectivity
In order to assess whether prion infected neuronal cells may
release membrane-derived MVs that harbor the pathological
isoform of the prion protein (PrP
Sc) and prion infectivity, we
isolated MVs from cell culture supernatants of Rocky Mountain
Laboratory prion strain (RML)-infected and non-infected Neuro-
2a PK1 cells. We then assessed the presence of PrP
Sc by
immunoblot analysis and that of prion infectivity by in vitro and
in vivo infectivity transmission experiments. Specific detection of
PrP
Sc was achieved by the use of proteinase K (PK) digestion. The
Shedding of PrP
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Sc is partially resistant against PK
treatment, whereas the cellular isoform PrP
C is completely
degraded by this protease [62]. As shown in Figure 6, MVs
derived from infected cells harbored PK-resistant PrP, a clear
indication for the presence of PrP
Sc. Interestingly, the levels of
PrP
Sc detected in the purified MVs were higher than those
observed in the parental cell line (Fig. 6), suggesting that PrP
Sc is
enriched on the membrane of MVs. PrP
Sc was not detected, as
expected, in MVs secreted by non-infected Neuro-2a PK1 cells
(Fig. 6), confirming that PrP
Sc is released specifically from prion
infected neuronal cells.
MVs-dependent transmission of prion infectivity was then first
assayed by an in vitro infection approach. Noninfected Neuro-2a
PK1 cells were incubated in the presence of MVs isolated from cell
culture supernatants of infected and noninfected Neuro-2a PK1
cells, respectively. De novo amplification of PrP
Sc was then followed
for longer than 3 months post infection by cell blot assay (Fig. 7).
Conversion of the endogenous PrP
C into the prion disease-
associated pathological isoform PrP
Sc was only detected in Neuro-
2a PK1 cells treated with MVs derived from prion-infected but not
from non-infected donor cells (Fig. 7). Prion replication was
detected up to 30 passages after infection, indicating that MVs-
Figure 1. PrP
C detection in MVs from human plasma. MVs obtained from human plasma were analyzed for the presence of PrP
C. A: Western
blot analysis with anti-PrP monoclonal 6H4 antibody of MVs compared with human peripheral blood (PB). B: Cytofluorimetric analysis with an anti-
PrP (C-20 PE). MVs: MVs gated on the basis of forward and side scatter parameters using polystirene beads 0.8 mm as standard. Anti-PrP: MVs
stained by anti-PrP PE (C-20 PE) vs IgG PE with irrelevant specificity. Anti-LBPA: MVs stained by anti-LBPA, followed by PE-conjugated anti-mouse
IgG. Anti-MHC-I: MVs stained by anti-human MHC I vs IgG PE with irrelevant specificity.
doi:10.1371/journal.pone.0005057.g001
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recipient neuroblastoma cells and excluding that the detected
PrP
Sc could just be due to the persistence of the initial inoculum.
In order to further confirm the association of prion infectivity
with membrane-derived MVs and to determine prion titres, in vivo
biossay was performed in which purified MVs from infected and
non-infected Neuro-2a PK1 cells or cell lysates were intracere-
brally inoculated into tga20 indicator mice [49]. Incubation times
until development of terminal scrapie were determined and
infectious titres were calculated by comparing incubation times
against a calibration curve (Table 1). Indicator mice developed
clinical prion disease after inoculation with Rocky Mountain
Laboratory mouse-adapted prion strain (RML) at the three
dilutions tested, but not when they were inoculated with mock
control, as expected. Interestingly, membrane-derived MVs from
infected but not from non-infected Neuro-2a cells were capable of
transmitting prion disease to tga20 indicator mice, demonstrating
that MVs are infectious not only in vitro but also in vivo.
Furthermore, MVs-associated prion titres were higher than those
detected as cell-associated (Table 1), a finding confirming the
observation that MVs contain more PrP
Sc than the cells from
which they are derived (Fig. 6). On the other hand, MVs seem to
be a little less infectious than crude brain homogenate: indeed
mice challenged with 6610
22 dilution of RML (i.e. corresponding
to 10 mg of total brain protein) developed clinical prion disease
earlier than those challenged with MVs.
Discussion
MVs are normal constituents of blood plasma and are secreted
by leukocytes, endothelium, platelets and erythrocytes [50].
Interestingly, only one-third of the PrP
C in human blood is cell
Figure 2. Evidence for raft components in MVs from human
plasma. MVs obtained from human plasma were subjected to
ganglioside extraction and analyzed by TLC immunostaining. A:
reactivity of anti-GM3, followed by peroxidase-conjugated anti-mouse
IgM MoAb; B: reactivity of HRP-CTxB. MVs obtained from human plasma
were analyzed by Western blot using the anti-Fyn (FYN3) (C) and anti-
flotillin-2 (D). Inset: electron microscopy negative staining of MVs
obtained from human plasma.
doi:10.1371/journal.pone.0005057.g002
Figure 3. Co-immunoprecipitation of PrP
C with gangliosides
and p59 Fyn Kinase. MVs from human plasma were immunoprecip-
itated with anti-PrP (C-20). The immunoprecipitates were subjected to
ganglioside extraction and analyzed by TLC immunostaining or Western
Blot with polyclonal anti-Fyn antibody (FYN3). A: reactivity of anti-GM3
(MoAb GMR6) with standard GM3, PrP
C immunoprecipitate and
immunoprecipitate with IgG with irrelevant specificity. B: reactivity of
CTxB perox with standard GM1, PrP
C immunoprecipitate and immuno-
precipitate with IgG with irrelevant specificity. C: Western blot analysis
with anti-Fyn (FYN3) of human peripheral blood, PrP
C immunoprecip-
itate and immunoprecipitate with IgG with irrelevant specificity.
doi:10.1371/journal.pone.0005057.g003
Figure 4. Evidence for the presence of PrP
C in MVs from
neuronal cells. A MVs obtained from the Neuro-2a cells were
analyzed by Western blot using anti-PrP SAF-32. Crude brain
homogenate from wild type mice was included as positive control. B
Left: electron microscopy negative staining of MVs obtained from
Neuro-2a PK1 cells. Right: two representative examples of anti-PrP
C
specific staining on the surface of MVs obtained from Neuro-2a PK1
cells. PrP
C was revealed by immunogold labelling (10 nm) and indicated
on the images by the black arrows.
doi:10.1371/journal.pone.0005057.g004
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MVs are shed from the plasma membrane of eukaryotic cells,
mainly from those undergoing activation or apoptosis [22]. In this
context, it has previously been shown that thrombin stimulation
triggered a transient shedding of microvesicles from the platelet
surface. Of note, PrP
C is released initially in small quantities on
microvesicles and subsequently in higher levels on exosomes [33].
In the present study we demonstrated that PrP
c is present in
MVs from human plasma of healthy donors and that, among
MVs, PrP
c is associated with other lipid raft components. The
functional role of MVs is still largely unknown, however, some
evidence show that MVs components mainly arise from lipid rafts,
which therefore might be involved in setting up sorting platforms
to concentrate specific proteins within MVs, that could be destined
to extracellular secretion. It suggests that they may participate in a
variety of intercellular adhesion processes and induce cellular
responses [24]. Moreover, it has been demonstrated that blood as
well as plasma of animals experimentally infected with TSEs can
transmit TSE infection by transfusion [35,37]. Our results support
and extend these findings, showing the presence of PrP
C in MVs
from human plasma, as revealed by Western blot and cytofluori-
metric analysis results, and demonstrating that the whole signaling
complex is represented in these microparticles. Indeed, in MVs,
not only PrP
C, but also p59Fyn, as well as GM1 and GM3
gangliosides were revealed and co-immunoprecipitated with PrP
C,
demonstrating that all the signaling complex may be shed within
MVs. The presence of lipid rafts-associated signaling complex(es)
in MVs suggests a potential role for these microparticles in cell-to-
cell communication through MVs shedding and fusion.
It has previously been shown that neuronal cells release
exosomes containing numerous proteins and lipids similar to
those present in the membranes of the cells from which they
originate, including typical neuronal proteins such as the GluR2/3
subunits of glutamate receptors, the cell adhesion molecule L1
and, interestingly, PrP
C [61]. Here, we report for the first time that
neuronal cells also release plasma-derived MVs. Indeed, MVs
were isolated from the cell culture supernatants of two murine
neuronal cell lines (Neuro-2a and Neuro-2a PK1 cells). Electron
microscopy analyses of MVs preparations demonstrated the
presence of vesicles with a diameter ranging from 100 nm to
1 mm, a size compatible with that described for MVs purified from
other cells [23].
In this study, the association of PrP
C with MVs shed by murine
neuronal cells was demonstrated. The presence of PrP
C in MVs
released from both the Neuro-2a and the Neuro-2a PK1 cell lines
was shown by immunoblot analysis. Furthermore, IEM analysis of
Neuro-2a PK1 cells, a murine neuroblastoma cell line endoge-
nously expressing PrP
C, revealed the unevenly distribution of PrP
C
on the membrane of MVs, as well as on the cell plasma
membrane. Heterogeneity of PrP
C molecules is attributed mainly
to various degrees of N-glycosylation on asparagine residues
[64,65]. Interestingly, MV-associated PrP
C displayed an electro-
phoretic mobility pattern on SDS-polyacrylamide gels resembling
if not overlapping the one detected for cell-derived PrP
C,
suggesting that in MVs fully processed and mature PrP
C molecules
are incorporated during membrane shedding. However, in a
recently published work, a novel processing pathway that involves
the N-terminal modification of PrP
C and the selection of distinct
PrP
C glycoforms for incorporation into exosomes has been
described [31]. Thus, a more accurate and detailed analysis of
MV-associated PrP
C should be performed in order to verify
whether a similar processing pathway also occurs during
incorporation of PrP
C into plasma-derived MVs. The presence
of lipid raft components, such as the p59Fyn kinase, flotillin-2 and
the ganglioside GM2 was furthermore detected in MVs released
by the murine Neuro-2a cell line, suggesting that raft components
strictly associated with PrP
C on the cell plasma membrane are
recruited during the formation of MVs in neuronal cells. The
neuronal origin of the analyzed MVs was confirmed by the
Figure 5. Evidence for raft components in MVs from neuronal
cells. A MVs from Neuro-2a cells were subjected to ganglioside
extraction and analyzed by TLC immunostaining. a: reactivity of anti-
GM2 (GMR6 MoAb) with standard GM2. MVs obtained from the Neuro-
2a cells were analyzed by Western blot using different antibodies. b:
reactivity with anti-Flotillin-2; c: reactivity with anti-GAP-43. Crude brain
homogenate from wild type mice was included as positive control. B
Co-immunoprecipitation of PrP
C and gangliosides. MVs from Neuro-2a
cells were immunoprecipitated with anti-PrP (C-20). The immunopre-
cipitates were subjected to ganglioside extraction and analyzed by TLC
immunostaining: reactivity of anti-GM2 (GMR6 MoAb) with standard
GM2, PrP
C immunoprecipitate and immunoprecipitate with IgG with
irrelevant specificity. The immunoprecipitate was revealed as PrP
C,a s
detected by Western blot, using the anti-PrP monoclonal 6H4 antibody.
doi:10.1371/journal.pone.0005057.g005
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protein which binds to rafts via its acylated N-termini.
The growing interest in the presence of PrP
C in MVs is due to
the potential role of these microparticles in the propagation of the
disease. The release of PrP
C and infectious PrP
Sc by prion infected
epithelial (Rov cells), neuroglial (Mov cells) and neuronal cells
(GT1-7 cells) in association with exosomes has recently been
highlighted [30,31], suggesting that PrP
Sc-bearing exosomes may
provide a mechanism for intercellular transmission of infectious
prions in addition to cell-to-cell contact. Indeed it was found that
both PrP
Sc and PrP
C are present in cell culture supernatants in a
secreted, exosome-associated form and that exosomes bearing
PrP
Sc were infectious both in vitro and in vivo [30,31].
This work further extends these findings showing for the first
time that stably infected neuronal cells endogenously expressing
PrP
C shed plasma-derived MVs, which are carriers both of the
pathological isoform PrP
Sc and of prion infectivity. Noteworthy,
MVs isolated from cell culture supernatants of Rocky Mountain
Laboratory prion strain (RML)-infected Neuro-2a PK1 harbored
PK-resistant PrP, an indication for the presence of PrP
Sc.
Interestingly, the levels of PrP
Sc detected in the purified MVs
were higher than those observed in the parental cell line,
suggesting that PrP
Sc is enriched on the membrane of MVs. PrP
C
and PrP
Sc are GPI-anchored proteins known to partition into lipid
rafts [66,67] and the lipid raft-like nature of MVs membranes
argues for an efficient insertion of PrP
Sc in lipid raft-rich domains
of the plasma membrane involved in MVs formation. Further-
more, the evidence that lipid rafts play a role in the formation of
PrP
Sc in scrapie-infected culture cells [68,69] supports the
hypothesis of a preferential distribution of PrP
Sc within lipid rafts.
On the other hand, PrP
C but not PrP
Sc was detected in MVs
secreted by non-infected Neuro-2a PK1 cells, confirming that
PrP
Sc is released specifically from prion infected neuronal cells.
Thus, these findings clearly indicate that prion infected neuronal
cells such as the Neuro-2a PK1 shed plasma membrane-derived
MVs containing PrP
Sc.
The potential role of plasma membrane-derived MVs in prion
infectivity transmission was tested both in vitro and in vivo infection
models. This study demonstrates that PrP
Sc-bearing MVs can
transmit prion infectivity both in vitro and in vivo, indicating that
MVs contribute both to the intercellular mechanism(s) of PrP
C
diffusion and to the process of infectious prions intercellular
trafficking. Indeed, MVs isolated from cell culture supernatants of
infected but not from uninfected Neuro-2a PK1 cells were capable
of initiating de novo amplification of prions in the recipient cells.
Interestingly, prion replication was detected up to 30 passages after
infection, indicating that MV-dependent prion transmission
generated a persistent infection in the recipient neuroblastoma
cells. Hypothetically, PrP
C conversion may be initiated as a
consequence of the binding of PrP
Sc-bearing MVs to acceptor
cells. In this context, it is noteworthy that the topology of exosomal
and, most probably, of MVs membranes is identical to that of the
plasma membrane [70]. Alternatively, but not mutually exclusive,
MVs captured by the target cells could fuse with the cell surface or
be internalized by an unclear mode of entry to induce
conformational change of PrP
C at the cell surface and/or in
endocytic compartments, respectively. Moreover, in vivo biossay in
transgenic mice that overexpress murine PrP
C and are highly
susceptible to murine prions [50] clearly demonstrated that prion
Figure 6. Prion infected neuronal cells shed PrP
Sc bearing MVs. Left panel: Detection of PrP
Sc in MVs isolated from culture supernatants of
prion uninfected and infected Neuro-2a PK1 cells. Twenty mg total proteins of isolated MVs were PK digested. PrP
Sc was specifically detected in MVs
released by the infected but not from the uninfected N2a PK1 cells. Right panel: Detection of PrP
Sc in infected Neuro-2a PK1 cells. Two hundred and
fifty mg total proteins of cell lysates were PK digested. The presence of PK-resistant PrP
Sc was assessed with increasing amounts of proteinase K and
detected by the use of the 6H4 antibody. The positions of the molecular weight standards (in kilodaltons) are indicated.
doi:10.1371/journal.pone.0005057.g006
Figure 7. In vitro transmission of prion infectivity by PrP
Sc-
bearing MVs. Cell blot assay detecting de novo infected N2a PK1 cells
at serial culture passages. N2a PK1 cells were incubated with MVs
isolated from uninfected (Mvs
Uninf) or from infected (MVs
Inf) N2a PK1
cells. Mock and Chandler infections were also included as negative and
positive control, respectively. A time-dependent increase of PrP
Sc levels
was detected after proteinase K treatment (+PK).
doi:10.1371/journal.pone.0005057.g007
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Sc-harboring MVs shed by prion
infected murine neuronal cells. In fact, membrane-derived MVs
from infected but not those from uninfected Neuro-2a PK1 cells
were capable of transmitting prion disease to tga20 indicator mice.
These new findings suggest that plasma membrane-derived MVs
shed by prion infected cells could actively participate in the
intercellular trafficking of PrP
Sc and contribute to the transmission
of infectious prions. One may therefore postulate that MVs act as
carriers of prion infectivity during prion neuroinvasion and play a
pivotal role in the propagation of prion infectivity from neuron to
neuron, in this way contributing to the pathogenesis of the disease.
However, it does not exclude the possibility that also exosomes
may play an important role in secreted infectivity from the cells.
In conclusion, our data provide here evidence for the presence
of PrP
C in MVs in vivo, in human plasma, suggesting that these
MVs might be involved in the mechanism(s) of PrP
C paracrine as
well as endocrine diffusion and may also contribute to blood
transfusion-mediated transmission of prion diseases.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0005057.s001 (0.15 MB TIF)
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